Thromb Haemost 1983; 49(02): 081-083
DOI: 10.1055/s-0038-1657326
Original Article
Schattauer GmbH Stuttgart

Heparin Counteracts the Antiaggregating Effect of Prostacyclin by Potentiating Platelet Aggregation

Vittorio Bertelé
The Laboratory for Haemostasis and Thrombosis Research and the Laboratory of Cardiovascular Clinical Pharmacology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
,
Maria Carla Roncaglioni
The Laboratory for Haemostasis and Thrombosis Research and the Laboratory of Cardiovascular Clinical Pharmacology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
,
Maria Benedetta Donati
The Laboratory for Haemostasis and Thrombosis Research and the Laboratory of Cardiovascular Clinical Pharmacology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
,
Giovanni de Gaetano
The Laboratory for Haemostasis and Thrombosis Research and the Laboratory of Cardiovascular Clinical Pharmacology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
› Author Affiliations
Further Information

Publication History

Received 18 October 1982

Accepted 13 January 1983

Publication Date:
18 July 2018 (online)

Summary

It has recently been reported that heparin neutralizes the inhibitory effect of prostacyclin (PGI2) on human platelet aggregation. The mechanism of this interaction has not yet been unequivocally established. We present here evidence that heparin (Liquemin Roche) does not react directly with PGI2 but counteracts its inhibitory effect by potentiating platelet aggregation. In the absence of heparin, PGI2 was a less effective inhibitor of platelet aggregation induced by the combination of ADP and serotonin than by ADP alone. Moreover, the inhibitory effect of PGI2 was similarly reduced when increasing the concentrations of ADP (in the absence of heparin). The lack of a specific interaction between heparin and PGI2 is supported by the observation that, in the presence of heparin, other prostaglandins such as PGD2 and PGE1, and a non-prostanoid compound such as adenosine also appeared to lose their inhibitory potency. It is concluded that heparin opposes platelet aggregation inhibitory effect of PGI2 by enhancement of platelet aggregation.

 
  • References

  • 1 Saba HI, Saba SR, Blackburn CA, Haetmann RC, Mason RG. Heparin neutralization of PGI2: effects upon platelets. Science 1979; 205: 499-501
  • 2 Eldor A, Weksler BB. Heparin and dextran sulphate antagonize PGI2 inhibition of platelet aggregation. Thromb Res 1979; 16: 617-628
  • 3 MacIntyre DE, Handin RI, Rosenberg R, Salzman EW. Heparin opposes prostanoid and non-prostanoid platelet inhibitors by direct enhancement of aggregation. Thromb Res 1981; 22: 167-175
  • 4 Silver MJ, Smith JB, Ingerman C, Kocsis JJ. Arachidonic acid induces human platelet aggregation and prostaglandin formation. Prostaglandins 1973; 4: 863-875
  • 5 Di Minno G, Silver MJ, de Gaetano G. Prostaglandins as inhibitors of human platelet aggregation. Br J Haematol 1979; 43: 637-647
  • 6 Di Minno G, Bertelé V, Bianchi L, Barbieri B, Cerletti C, Dejana E, de Gaetano G, Silver MJ. Effects of an epoxymethano stable analogue of prostaglandin endoperoxides (U-46619) on human platelets. Thromb Haemostas 1981; 45: 103-106
  • 7 de Gaetano G, Vermylen J. Effect of heparin on platelets. Lancet 1972; 2: 376-377